Novel arid established CYP2A6 alleles impair in vivo nicotine metabolism in a population of black African descent

Human Mutation

Volumn 29, Issue 5, 2008, Pages 679-688

  Mwenifumbo, Jill C ^a   Al Koudsi, Nael ^a   Man, Ki Ho ^a   Zhou, Qian ^a   Hoffmann, Ewa B ^a,b   Sellers, Edward M ^a   Tyndale, Rachel F ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

3HC COT; Black African descent; CYP2A6; Genetic variation; Nicotine metabolism

Indexed keywords

3' HYDROXYCOTININE; COTININE; CYTOCHROME P450 2A6; NICOTINE; COUMARIN 7 HYDROXYLASE; COUMARIN 7-HYDROXYLASE; UNSPECIFIC MONOOXYGENASE;

AFRICA; ARTICLE; BLOOD SAMPLING; DRUG METABOLISM; ENZYME ACTIVITY; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HUMAN; IN VIVO STUDY; KINETICS; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PHENOTYPE; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN FUNCTION; SEQUENCE ANALYSIS; STATISTICAL SIGNIFICANCE; ADULT; ALLELE; CATALYSIS; FEMALE; GENETICS; MALE; METABOLISM; MIDDLE AGED; NEGRO; OXIDATION REDUCTION REACTION; PROMOTER REGION;

NICOTIANA TABACUM;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ALLELES; ARYL HYDROCARBON HYDROXYLASES; CATALYSIS; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NICOTINE; OXIDATION-REDUCTION; PROMOTER REGIONS (GENETICS);

EID: 42949141477     PISSN: 10597794     EISSN: None     Source Type: Journal    
DOI: 10.1002/humu.20698     Document Type: Article

References (52)

1. Al Koudsi N, Mwenifumbo JC, Sellers EM, Benowitz NL, Swan GE, Tyndale RF. 2006. Chatacterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics. Eur J Clin Pharmacol 62:481-484.
2. Benowitz NL, Jacob P 3rd. 2000. Effects of cigarette smoking and carbon monoxide on nicotine and cotinine metabolism. Clin Pharmacol Ther 67:653-659.
3. Benowitz NL, Lessov-Schlaggar CN, Swan GE, Jacob P 3rd. 2006a. Female sex and oral contraceptive use accelerate nicotine metabolism. Clin Pharmacol Ther 79:480-488.
4. Benowitz NL, Swan GE, Jacob P 3rd, Lessov-Schlaggar CN, Tyndale RF. 2006b. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clin Pharmacol Ther 80:457-467.
5. Carter B, Long T, Cinciripini P. 2004- A meta-analytic review of the CYP2A6 genotype and smoking behavior. Nicotine Tob Res 6:221-227.
6. Dempsey D, Tutka P, Jacob P 3rd, Allen F, Schoedel K, Tyndale RF, Benowitz NL. 2004. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther 76:64-72.
7. Ding S, Lake BG, Friedberg T, Wolf CR. 1995. Expression and alternative splicing of the cytochrome P-450 CYP2A7. Biochem J 306(Pt 1):161-166.
8. Fujieda M, Yamazaki H, Saito T, Kiyotani K, Gyamfi MA, Sakurai M, Dosaka-Akita H, Sawamura Y, Yokota J, Kunitoh H, Kamataki T. 2004. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. Carcinogenesis 25:2451-2458.
9. Fukami T, Nakajima M, Yoshida R, Tsuchiya Y, Fujiki Y, Katoh M, McLeod HL, Yokoi T. 2004. A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo. Clin Pharmacol Ther 76:519-527.
10. Fukami T, Nakajima M, Higashi E, Yamanaka H, McLeod HL, Yokoi T. 2005. A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity. Biochem Phatmacol 70:801-808.
11. Fukami T, Nakajima M, Yamanaka H, Fukushima Y, McLeod HL, Yokoi T. 2007. A novel duplication type of CYP2A6 gene in African-American population. Drug Metab Dispos 35:515-520.
12. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. 2007. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther (in press) [Epub ahead of print].
13. Goodz SD, Tyndale RF. 2002. Genotyping human CYP2A6 variants. Methods Enzymol 357:59-69.
14. Gu DF, Hinks LJ, Morton NE, Day IN. 2000. The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit. Ann Hum Genet 64(Pt 5):383-390.
15. Haberl M, Anwald B, Klein K, Weil R, Fuss C, Gepdiremen A, Zanger UM, Meyer UA, Wojnowski L. 2005. Three haplotypes associated with CYP2A6 phenotypes in Caucasians. Pharmacogenet Genomics 15:609-624.
16. Haiman CA, Stram DO, Wilkens LR, Pike MC, Kolonel LN, Henderson BE, Le Marchand L. 2006. Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med 354:333-342.
17. Hakooz N, Hamdan I. 2007. Effects of dietary broccoli on human in vivo caffeine metabolism: a pilot study on a group of Jordanian volunteers. Curr Drug Metab 8:9-15.
18. Hasler J, Samuelsson T, Strub K. 2007. Useful 'junk': Alu RNAs in the human transcriptome. Cell Mol Life Sci 64:1793-1800.
19. Henningfield JE, Miyasato K, Jasinski DR. 1985. Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine. J Pharmacol Exp Ther 234:1-12.
20. Ho MK, Mwenifumbo J, Zhao B, Gillam E, Tyndale R. 2008. A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent. Pharmacogenet Genomics 18:67-75.
21. Hoffman SM, Nelson DR, Keeney DS. 2001. Organization, structute and evolution of the CYP2 gene cluster on human chromosome 19. Pharmacogenetics 11:687-698.
22. Iwahashi K, Waga C, Takimoto T. 2004. Whole deletion of CYP2A6 gene (CYP2A6AST;4C) and smoking behavior. Neuropsychobiology 49:101-104.
23. Kitagawa K, Kunugita N, Kitagawa M, Kawamoto T. 2001. CYP2A6*6, a novel polymorphism in cytochrome P450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity. J Biol Chem 276:17830-17835.
24. Lewis DF. 2003. Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes. Arch Biochem Biophys 409:32-44.
25. Malaiyandi V, Lerman C, Benowitz NL, Jepson C, Patterson F, Tyndale RF. 2006. Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Mol Psychiatry 11:400-409.
26. Messina ES, Tyndale RF, Sellers EM. 1997. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther 282:1608-1614.
27. Minematsu N, Nakamura H, Furuuchi M, Nakajima T, Takahashi S, Tateno H, Ishizaka A. 2006. Limitation of cigarette consumption by CYP2A6*4, *7 and *9 polymorphisms. Eur Respir J 27:289-292.
28. Mwenifumbo JC, Myers MG, Wall TL, Lin SK, Sellers EM, Tyndale RF. 2005. Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method. Pharmacogenet Genomics 15:189-192.
29. Mwenifumbo JC, Tyndale RF. 2007. Genetic variability in CYP2A6 and the pharmacokinetics of nicotine. Pharmacogenomics 8:1385-1402.
30. Mwenifumbo JC, Sellers EM, Tyndale RF. 2007. Nicotine metabolism and CYP2A6 activity in a population of black African descent: impact of gender and light smoking. Drug Alcohol Depend 89:24-33.
31. Mwenifumbo JC, Lessov-Schlaggar CN, Zhou Q, Krasnow RE, Swan GE, Benowitz NL, Tyndale RF. 2008. Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolism. Clin Pharmacol Ther 83:115-121.
32. Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K, Funae Y, Shimada N, Kamataki T, Kuroiwa Y. 1996a. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 24:1212-1217.
33. Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K, Funae Y, Shimada N, Kamataki T, Kuroiwa Y. 1996b. Characterization of CYP2A6 involved in 3′-hydroxylation of cotinine in human liver microsomes. J Pharmacol Exp Ther 277:1010-1015.
34. Nakajima M, Fukami T, Yamanaka H, Higashi E, Sakai H, Yoshida R, Kwon JT, McLeod HL, Yokoi T. 2006. Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther 80:282-297.
35. Oscarson M, McLellan RA, Gullsten H, Yue QY, Lang MA, Bemal ML, Sinues B, Hirvonen A, Raunio H, Pelkonen O, Ingelman-Sundherg M. 1999. Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett 448:105-110.
36. Pichard-Garcia L, Hyland R, Baulieu J, Fahre JM, Milton A, Maurel P. 2000. Human hepatocytes in primary culture predict lack of cytochrome P-450 3A4 induction by eletriptan in vivo. Drug Metab Dispos 28:51-57.
37. Pitarque M, von Richter O, Oke B, Berkkan H, Oscarson M, Ingelman-Sundberg M. 2001. Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. Biochem Biophys Res Commun 284:455-460.
38. Pitarque M, von Richter O, Rodriguez-Antona C, Wang J, Oscarson M, Ingelman-Sundberg M. 2004. A nicotine C-oxidase gene (CYP2A6) polymorphism important for promoter activity. Hum Mutat 23:258-266.
39. Pritchard MP, Ossetian R, Li DN, Henderson CJ, Burchell B, Wolf CR, Friedberg T. 1997. A general strategy for the expression of recombinant human cytochrome P450s in Escherichia coli using bacterial signal peptides: expression of CYP3A4, CYP2A6, and CYP2E1. Arch Biochem Biophys 345:342-354.
40. Rao Y, Hoffmann E, Zia M, Bodin L, Zeman M, Sellers EM, Tyndale RF. 2000. Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol Pharmacol 58:747-755.
41. Saito S, Iida A, Sekine A, Kawauchi S, Higuchi S, Ogawa C, Nakamura Y. 2003. Catalog of 680 variations among eight cytochrome p450 (CYP) genes, nine esterase genes, and two other genes in the Japanese population. J Hum Genet 48:249-270.
42. Satarug S, Nishijo M, Ujjin P, Vanavanitkun Y, Baker JR, Moore MR. 2004. Effects of chronic exposure to low-level cadmium on renal tubular function and CYP2A6-mediated coumarin metabolism in healthy human subjects. Toxicol Lett 148:187-197.
43. Schoedel KA, Sellers EM, Palmour R, Tyndale RF. 2003. Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration. Mol Pharmacol 63:96-104.
44. Schoedel KA, Hoffmann EB, Rao Y, Sellers EM, Tyndale RF. 2004. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 14:615-626.
45. Siu EC, Wildenauer DB, Tyndale RF. 2006. Nicotine self-administration in mice is associated with rates of nicotine inactivation by CYP2A5. Psychopharmacology (Berl) 184:401-408.
46. Solus JF, Arietta BJ, Harris JR, Sexton DP, Steward JQ, McMunn C, Ihrie P, Mehall JM, Edwards TL, Dawson EP. 2004. Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 5:895-931.
47. USDHHS. 1998. Tobacco use among U.S. racial/ethnic minority groups: African Americans, American Indians and Alaska Natives, Asian Americans and Pacific Islanders, and Hispanics: a report of the Surgeon General. 332 p. Available at: www.cdc.gov/tobacco/data_statistics/sgr/sgr_1998/sgr-min-sgr2.htm. Last accessed: 4 December 2007.
48. von Richter O, Pitarque M, Rodriguez-Antona C, Testa A, Mantovani R, Oscarson M, Ingelman-Sundberg M. 2004. Polymorphic NF-Y dependent regulation of human nicotine C-oxidase (CYP2A6). Pharmacogenetics 14:369-379.
49. Wortham M, Czerwinski M, He L, Parkinson A, Wan YJ. 2007. Expression of constitutive andtostane receptor, hepatic nuclear factor 4 alpha, and P450 oxidoreductase genes determines interindividual variability in basal expression and activity of a broad scope of xenobiotic metabolism genes in the human liver. Drug Metab Dispos 35:1700-1710.
50. Yamanaka H, Nakajima M, Nishimura K, Yoshida R, Fukami T, Katoh M, Yokoi T. 2004. Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted. Eur J Pharm Sci 22:419-425.
51. Yano JK, Hsu MH, Griffin KJ, Stout CD, Johnson EF. 2005. Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen. Nat Struct Mol Biol 12:822-823.
52. Yoshida R, Nakajima M, Watanabe Y, Kwon JT, Yokoi T. 2002. Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism. Br J Clin Pharmacol 54:511-517.